Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An acute bacterial disease caused by Neisseria meningitides that presents usually, but not always, with a rash (non blanching petechial or purpuric rash), progressively developing signs of meningitis (fever, vomiting, headache, photophobia, and neck stiffness) and later leading to confusion, delirium and drowsiness. Neck stiffness and photophobia are often absent in infants and young children who may manifest nonspecific signs such as irritability, inconsolable crying, poor feeding, and a bulging fontanel. Meningococcal meningitis may also present as part of early or late onset sepsis in neonates. The disease is potentially fatal. Surviving patients may develop neurological sequelae that include sensorineural hearing loss, seizures, spasticity, attention deficits and intellectual disability.
Features include very common findings: Fever, Increased CSF protein concentration, Hypoglycorrhachia, and CSF pleocytosis and others; and common findings: Photophobia, Petechiae, Skin rash, and Anorexia and others. 35 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 7 | Nuchal rigidity, Headache, Irritability |
Biomarker and diagnostic research for meningococcal meningitis has been reported in the published literature.
Phenotype severity distribution: 6 very common features, 9 common features.
Estimated prevalence: 1-9 in 100,000 (Uncommon).
6 clinical trials registered, 1 recruiting. Interventions under study include biologic therapy. Pipeline includes 1 PHASE4, 3 PHASE3, 1 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06700148](https://clinicaltrials.gov/study/NCT06700148) |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 4:29 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Lab test results |
3 |
Increased CSF protein concentration, Elevated CRP (inflammation marker) (elevated circulating c-reactive protein concentration), Increased circulating procalcitonin concentration |
Digestive system | 2 | Anorexia, Projectile vomiting |
Metabolism | 1 | Fever |
Skin | 1 | Skin rash |
Kidneys and urinary system | 1 | Reduced kidney function (renal insufficiency) |
Ears | 1 | Hearing loss (hearing impairment) |
Heart and blood vessels | 1 | Stroke |
Lungs and breathing | 1 | Neonatal respiratory distress |
Pregnancy and birth | 1 | Neonatal respiratory distress |
Blood and immune system | 1 | Acute disseminated intravascular coagulation |
A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds
PHASE3 |
CanSino Biologics Inc. |
UNKNOWN |
[NCT06832514](https://clinicaltrials.gov/study/NCT06832514) | Investigating Gender and Sex Differences in Immune Responses Through Vaccination of Transgender and Cisgender Persons | PHASE4 | University Ghent | RECRUITING |
[NCT06337071](https://clinicaltrials.gov/study/NCT06337071) | A Study of the ACYW135 Meningococcal Polysaccharide Conjugate Vaccine | PHASE2 | Aimei Vacin BioPharm (Zhejiang) Co., Ltd. | UNKNOWN |
[NCT07374510](https://clinicaltrials.gov/study/NCT07374510) | Phase Ia Clinical Trial of Group ACYW135X Meningococcal Conjugate Vaccine | PHASE1 | Sinovac Life Sciences Co., Ltd. | NOT_YET_RECRUITING |
[NCT06131554](https://clinicaltrials.gov/study/NCT06131554) | A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years | PHASE3 | CanSino Biologics Inc. | UNKNOWN |
66 publications have been identified in PubMed for meningococcal meningitis. Research spans Case Report / Case Series (32%), Epidemiology / Natural History (29%), and Basic Science / Preclinical (18%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 21 | 32% |
Disease patterns and progression | 19 | 29% |
Laboratory research | 12 | 18% |
Research summaries | 7 | 11% |
Testing and diagnosis research | 4 | 6% |
New treatment approaches | 2 | 3% |
Clinical study results | 1 | 2% |
Rausch-Phung EA (2026). [PMID: 31751039](https://pubmed.ncbi.nlm.nih.gov/31751039/). *Unknown Journal*. [Epidemiology / Natural History]
Brusletto BS (2026). [PMID: 42112460](https://pubmed.ncbi.nlm.nih.gov/42112460/). *Front Cell Infect Microbiol*. [Basic Science / Preclinical]
Al-Dahash K (2026). [PMID: 42005178](https://pubmed.ncbi.nlm.nih.gov/42005178/). *Cureus*. [Case Report / Case Series]
Jin H (2026). [PMID: 42206698](https://pubmed.ncbi.nlm.nih.gov/42206698/). *Biopreserv Biobank*. [Basic Science / Preclinical]
Delport D (2026). [PMID: 41559840](https://pubmed.ncbi.nlm.nih.gov/41559840/). *BMC global and public health*. [Diagnostic / Biomarker]
Oyebanji O (2026). [PMID: 41810010](https://pubmed.ncbi.nlm.nih.gov/41810010/). *Journal of public health in Africa*. [Epidemiology / Natural History]
Levy C (2026). [PMID: 41800559](https://pubmed.ncbi.nlm.nih.gov/41800559/). *Journal of the Pediatric Infectious Diseases Society*. [Epidemiology / Natural History]
Li D (2026). [PMID: 41888240](https://pubmed.ncbi.nlm.nih.gov/41888240/). *Scientific reports*. [Epidemiology / Natural History]
Muyidi AA (2026). [PMID: 41894900](https://pubmed.ncbi.nlm.nih.gov/41894900/). *Journal of infection and public health*. [Review / Meta-Analysis]
Altelly A (2026). [PMID: 41939548](https://pubmed.ncbi.nlm.nih.gov/41939548/). *Cureus*. [Case Report / Case Series]